 Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Descriptor ID |
D006528
|
| MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
| Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Hepatocellular Cancer
- Cancer, Hepatocellular
- Cancers, Hepatocellular
- Hepatocellular Cancers
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma, Adult
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in this website by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 1 | 0 | 1 | | 1985 | 2 | 2 | 4 | | 1986 | 0 | 1 | 1 | | 1987 | 1 | 0 | 1 | | 1988 | 1 | 1 | 2 | | 1989 | 1 | 0 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 1 | 1 | 2 | | 1992 | 1 | 0 | 1 | | 1993 | 0 | 2 | 2 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 3 | 5 | | 1996 | 1 | 1 | 2 | | 1997 | 4 | 0 | 4 | | 1998 | 2 | 1 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 4 | 1 | 5 | | 2001 | 8 | 1 | 9 | | 2002 | 5 | 0 | 5 | | 2003 | 6 | 3 | 9 | | 2004 | 4 | 3 | 7 | | 2005 | 7 | 4 | 11 | | 2006 | 6 | 2 | 8 | | 2007 | 4 | 2 | 6 | | 2008 | 5 | 1 | 6 | | 2009 | 8 | 4 | 12 | | 2010 | 5 | 3 | 8 | | 2011 | 10 | 1 | 11 | | 2012 | 18 | 0 | 18 | | 2013 | 17 | 1 | 18 | | 2014 | 8 | 2 | 10 | | 2015 | 13 | 3 | 16 | | 2016 | 7 | 4 | 11 | | 2017 | 8 | 2 | 10 | | 2018 | 10 | 2 | 12 | | 2019 | 10 | 1 | 11 | | 2020 | 11 | 0 | 11 | | 2021 | 13 | 2 | 15 | | 2022 | 10 | 0 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles.
-
Parikh ND, Mehta N, Hoteit MA, Yang JD, John BV, Moon AM, Salgia RJ, Pillai A, Kassab I, Saeed N, Thyssen E, Nathani P, McKinney J, Chan W, Durkin C, Connor M, Alsudaney M, Konjeti R, Durand B, Nissen NN, Kim HP, Paknikar R, Rich NE, Schipper MJ, Singal AG. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.
-
Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305.
-
Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
-
Brankovic M, Jovanovic I, Dukic M, Radonjic T, Opric S, Klašnja S, Zdravkovic M. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. Int J Mol Sci. 2022 May 05; 23(9).
-
Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
-
Singh J, Wozniak A, Cotler SJ, Dhanarajan A, Aldrich D, Park D, Kasia C, Schmidt B, Scaglione S. Combined Use of Aspirin and Statin is Associated With a Decreased Incidence of Hepatocellular Carcinoma. J Clin Gastroenterol. 2022 04 01; 56(4):369-373.
-
Athavale D, Song Z, Desert R, Han H, Das S, Ge X, Komakula SSB, Chen W, Gao S, Lantvit D, Guzman G, Nieto N. Ablation of high-mobility group box-1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice. Hepatol Commun. 2022 08; 6(8):2155-2169.
-
Aniemeka C, Pillai AA. HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV. Dig Dis Sci. 2022 08; 67(8):3483-3484.
-
Yu Q, Knight G, Karani K, Fergus J, Leef J, Funaki B, Ahmed O. Real-time arteriography-directed percutaneous microwave ablation for small or poorly characterized hepatic lesions using hybrid Angio-CT. Abdom Radiol (NY). 2022 04; 47(4):1457-1463.
-
Wang J, Pillai AA. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther. 2022 02; 55(4):479-480.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|